RecruitingMetabolic Dysfunction-Associated Steatohepatitis

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

Eligible age

18–75 yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

Sponsor: Boston Pharmaceuticals

You may qualify if…

✓ Ability to understand and sign a written informed consent form (ICF)
✓ Age 18 through 75 years at enrollment
✓ History or presence of 2 or more of the 5 components of metabolic syndrome
✓ Liver biopsy confirmation of MASH consistent with stage F4 fibrosis
✓ Other inclusion criteria may apply.

You may not qualify if…

✕ Individuals with chronic liver disease from other causes, or any history or evidence of decompensated liver disease
✕ History of type 1 diabetes
✕ Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 × the upper limit of normal (ULN)
✕ Other exclusion criteria may apply.